Literature DB >> 24139870

Transcriptional responses of neonatal mouse lung to hyperoxia by Nrf2 status.

Sharon A McGrath-Morrow1, Thomas Lauer, Joseph M Collaco, Armando Lopez, Deepti Malhotra, Yuriy O Alekseyev, Enid Neptune, Robert Wise, Shyam Biswal.   

Abstract

UNLABELLED: Hyperoxia exposure can inhibit alveolar growth in the neonatal lung through induction of p21/p53 pathways and is a risk factor for the development of bronchopulmonary dysplasia (BPD) in preterm infants. We previously found that activation of nuclear factor erythroid 2 p45-related factor (Nrf2) improved survival in neonatal mice exposed to hyperoxia likely due to increased expression of anti-oxidant response genes. It is not known however, whether hyperoxic induced Nrf2 activation attenuates the growth impairment caused by hyperoxia in neonatal lung. To determine if Nrf2 activation modulates cell cycle regulatory pathway genes associated with growth arrest we examined the gene expression in the lungs of Nrf2(-/-) and Nrf2(+/+) neonatal mice at one and 3days of hyperoxia exposure.
METHODS: Microarray analysis was performed in neonatal Nrf2(+/+) and Nrf2(-/-) lungs exposed to one and 3days of hyperoxia. Sulforaphane, an inducer of Nrf2 was given to timed pregnant mice to determine if in utero exposure attenuated p21 and IL-6 gene expression in wildtype neonatal mice exposed to hyperoxia.
RESULTS: Cell cycle regulatory genes were induced in Nrf2(-/-) lung at 1day of hyperoxia. At 3days of hyperoxia, induction of cell cycle regulatory genes was similar in Nrf2(+/+) and Nrf2(-/-) lungs, despite higher inflammatory gene expression in Nrf2(-/-) lung.
CONCLUSION: p21/p53 pathways gene expression was not attenuated by Nrf2 activation in neonatal lung. In utero SUL did not attenuate p21 expression in wildtype neonatal lung exposed to hyperoxia. These findings suggest that although Nrf2 activation induces expression of anti-oxidant genes, it does not attenuate alveolar growth arrest caused by exposure to hyperoxia.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alveolar growth inhibition; CLDP; Cell cycle regulatory genes; Chronic lung disease of prematurity; Hyperoxia; Inflammation; Nrf2; chronic lung disease of prematurity; nuclear factor erythroid 2 p45-related factor

Mesh:

Substances:

Year:  2013        PMID: 24139870      PMCID: PMC3875154          DOI: 10.1016/j.cyto.2013.09.021

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  29 in total

1.  Crosstalk of EDA-A2/XEDAR in the p53 signaling pathway.

Authors:  Chizu Tanikawa; Cui Ri; Vinod Kumar; Yusuke Nakamura; Koichi Matsuda
Journal:  Mol Cancer Res       Date:  2010-05-25       Impact factor: 5.852

2.  Induction of p21WAF/CIP1 during hyperoxia.

Authors:  S A McGrath
Journal:  Am J Respir Cell Mol Biol       Date:  1998-02       Impact factor: 6.914

3.  An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.

Authors:  K Itoh; T Chiba; S Takahashi; T Ishii; K Igarashi; Y Katoh; T Oyake; N Hayashi; K Satoh; I Hatayama; M Yamamoto; Y Nabeshima
Journal:  Biochem Biophys Res Commun       Date:  1997-07-18       Impact factor: 3.575

Review 4.  Pathogenesis of bronchopulmonary dysplasia.

Authors:  Patricia R Chess; Carl T D'Angio; Gloria S Pryhuber; William M Maniscalco
Journal:  Semin Perinatol       Date:  2006-08       Impact factor: 3.300

Review 5.  p53 and ATM: cell cycle, cell death, and cancer.

Authors:  S E Morgan; M B Kastan
Journal:  Adv Cancer Res       Date:  1997       Impact factor: 6.242

6.  Altered regulation of G1 cyclins in oxidant-induced growth arrest of lung alveolar epithelial cells. Accumulation of inactive cyclin E-DCK2 complexes.

Authors:  S Corroyer; B Maitre; V Cazals; A Clement
Journal:  J Biol Chem       Date:  1996-10-11       Impact factor: 5.157

7.  Human-specific induction of glutathione peroxidase-3 by proteasome inhibition in cardiovascular cells.

Authors:  Kera Westphal; Verena Stangl; Michael Fähling; Henryk Dreger; Andrea Weller; Gert Baumann; Karl Stangl; Silke Meiners
Journal:  Free Radic Biol Med       Date:  2009-09-17       Impact factor: 7.376

8.  Functional and pathological effects of prolonged hyperoxia in neonatal mice.

Authors:  B B Warner; L A Stuart; R A Papes; J R Wispé
Journal:  Am J Physiol       Date:  1998-07

9.  Increased activity of interleukin-6 but not tumor necrosis factor-alpha in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia.

Authors:  A Bagchi; R M Viscardi; V Taciak; J E Ensor; K A McCrea; J D Hasday
Journal:  Pediatr Res       Date:  1994-08       Impact factor: 3.756

10.  Accumulation of p21(Cip1/WAF1) during hyperoxic lung injury in mice.

Authors:  M A O'Reilly; R J Staversky; R H Watkins; W M Maniscalco
Journal:  Am J Respir Cell Mol Biol       Date:  1998-11       Impact factor: 6.914

View more
  22 in total

1.  The genome-wide transcriptional response to neonatal hyperoxia identifies Ahr as a key regulator.

Authors:  Soumyaroop Bhattacharya; Zhongyang Zhou; Min Yee; Chin-Yi Chu; Ashley M Lopez; Valerie A Lunger; Siva Kumar Solleti; Emily Resseguie; Bradley Buczynski; Thomas J Mariani; Michael A O'Reilly
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-08-22       Impact factor: 5.464

2.  Role of GDF15 (growth and differentiation factor 15) in pulmonary oxygen toxicity.

Authors:  Kirti Kumar Tiwari; Bhagavatula Moorthy; Krithika Lingappan
Journal:  Toxicol In Vitro       Date:  2015-05-21       Impact factor: 3.500

3.  Sex-specific differences in the modulation of Growth Differentiation Factor 15 (GDF15) by hyperoxia in vivo and in vitro: Role of Hif-1α.

Authors:  Yuhao Zhang; Weiwu Jiang; Lihua Wang; Krithika Lingappan
Journal:  Toxicol Appl Pharmacol       Date:  2017-07-20       Impact factor: 4.219

4.  Gene Expression Profiling Identifies Cell Proliferation and Inflammation as the Predominant Pathways Regulated by Aryl Hydrocarbon Receptor in Primary Human Fetal Lung Cells Exposed to Hyperoxia.

Authors:  Binoy Shivanna; Suman Maity; Shaojie Zhang; Ananddeep Patel; Weiwu Jiang; Lihua Wang; Stephen E Welty; John Belmont; Cristian Coarfa; Bhagavatula Moorthy
Journal:  Toxicol Sci       Date:  2016-04-21       Impact factor: 4.849

5.  Neonatal hyperoxia promotes asthma-like features through IL-33-dependent ILC2 responses.

Authors:  In Su Cheon; Young Min Son; Li Jiang; Nicholas P Goplen; Mark H Kaplan; Andrew H Limper; Hirohito Kita; Sophie Paczesny; Y S Prakash; Robert Tepper; Shawn K Ahlfeld; Jie Sun
Journal:  J Allergy Clin Immunol       Date:  2017-12-15       Impact factor: 10.793

6.  Thioredoxin Reductase Inhibition Attenuates Neonatal Hyperoxic Lung Injury and Enhances Nuclear Factor E2-Related Factor 2 Activation.

Authors:  Qian Li; Stephanie B Wall; Changchun Ren; Markus Velten; Cynthia L Hill; Morgan L Locy; Lynette K Rogers; Trent E Tipple
Journal:  Am J Respir Cell Mol Biol       Date:  2016-09       Impact factor: 6.914

7.  Sexual dimorphism of the pulmonary transcriptome in neonatal hyperoxic lung injury: identification of angiogenesis as a key pathway.

Authors:  Cristian Coarfa; Yuhao Zhang; Suman Maity; Dimuthu N Perera; Weiwu Jiang; Lihua Wang; Xanthi Couroucli; Bhagavatula Moorthy; Krithika Lingappan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-17       Impact factor: 5.464

8.  Potential therapeutic targets in Nrf2-dependent protection against neonatal respiratory distress disease predicted by cDNA microarray analysis and bioinformatics tools.

Authors:  Hye-Youn Cho; Xuting Wang; Jianying Li; Douglas A Bell; Steven R Kleeberger
Journal:  Curr Opin Toxicol       Date:  2016-10-29

9.  Thiol-Redox Regulation in Lung Development and Vascular Remodeling.

Authors:  Gaston Ofman; Trent E Tipple
Journal:  Antioxid Redox Signal       Date:  2019-03-04       Impact factor: 8.401

Review 10.  Update on Molecular Biology of Lung Development--Transcriptomics.

Authors:  Thomas J Mariani
Journal:  Clin Perinatol       Date:  2015-12       Impact factor: 3.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.